Inovio Pharmaceuticals, Inc. is a bio pharmaceutical company. It develops active DNA immunotherapies for cancer and infectious diseases. The company&#x27;s portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. Its pipeline consists vgx-3100, ino-3122, ino-3106, pennvax-b and pennvax-g. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
